Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsMolecular Targeted Therapeutics

PUBLISHER: Grand View Research | PRODUCT CODE: 1678517

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1678517

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends:

The global antibody drug conjugates contract manufacturing market size is expected to reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Antibody Drug Conjugates Contract Manufacturing Market Report Highlights:

  • Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated to witness the fastest CAGR during the forecast period.
  • Based on linker, the market is segmented into cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
  • The antibody drug conjugates contract manufacturing market in North America is expected to witness the fastest CAGR over the forecast period.
  • Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing to supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.
Show more
Product Code: GVR-4-68039-623-5

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives
    • 1.10.1. Objective-1
    • 1.10.2. Objective-2
    • 1.10.3. Objective-3

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Cancer
      • 3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
      • 3.2.1.3. Increasing R&D Activities on ADCs
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Quality Issues While Outsourcing
      • 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Condition Estimates & Trend Analysis

  • 4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Segment Dashboard
  • 4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Movement Analysis
  • 4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Condition, 2018 - 2030 (USD Million)
  • 4.4. Myeloma
    • 4.4.1. Myeloma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.5. Lymphoma
    • 4.5.1. Lymphoma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.6. Breast Cancer
    • 4.6.1. Breast Cancer Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 5. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Linker Estimates & Trend Analysis

  • 5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Segment Dashboard
  • 5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Movement Analysis
  • 5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Linker, 2018 - 2030 (USD Million)
  • 5.4. Cleavable Linker
    • 5.4.1. Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
  • 5.5. Non-Cleavable Linker
    • 5.5.1. Non-Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antibody Drug Conjugates (ADC) Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. North America
    • 6.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Competitive Scenario
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Competitive Scenario
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Competitive Scenario
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. Sterling
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Service Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Recipharm AB
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Service Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Lonza
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Service Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Catalent, Inc.
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Service Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Sartorius AG
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Service Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Wuxi Biologics
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Service Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Samsung Biologics
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Service Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Piramal Group (Piramal Pharma Solutions)
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Service Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Service Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Merck KGaA
      • 7.3.10.1. Company Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Service Benchmarking
      • 7.3.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68039-623-5

List of Tables

  • Table 1 Information Procurement
  • Table 2 Primary Research Pattern
  • Table 3 Market Research Approaches
  • Table 4 Value Chain-Based Sizing & Forecasting
  • Table 5 Market Formulation & Validation
  • Table 6 Antibody Drug Conjugates (ADC) Contract Manufacturing, Market Segmentation
  • Table 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Table 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Table 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Table 10 Porter's Five Forces Analysis
  • Table 11 Regional Marketplace: Key Takeaways
  • Table 12 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Myeloma, 2018 - 2030 (USD Million)
  • Table 13 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Lymphoma, 2018 - 2030 (USD Million)
  • Table 14 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Breast Cancer, 2018 - 2030 (USD Million)
  • Table 15 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Table 16 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Cleavable Linker, 2018 - 2030 (USD Million)
  • Table 17 Global Antibody Drug Conjugates (ADC) Contract Manufacturing, for Non-cleavable Linker, 2018 - 2030 (USD Million)
  • Table 18 Regional Outlook, 2024 & 2030
  • Table 19 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 20 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 21 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 22 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 23 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 24 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 25 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 26 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 27 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 28 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 31 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 33 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 34 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 35 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 36 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 37 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 38 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 39 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 40 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 41 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 42 MEA Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 43 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 44 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 45 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Table 46 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 List of Secondary Sources
  • Fig. 2 List of Abbreviations
  • Fig. 3 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 4 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 5 Global Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Region, 2018 - 2030 (USD Million)
  • Fig. 6 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 7 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 8 North America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 9 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 10 U.S. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 11 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 12 Canada Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 13 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 14 Mexico Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 15 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 16 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 17 Europe Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 18 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 19 Germany Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 20 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 21 UK Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 22 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 23 France Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 24 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 25 Italy Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 26 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 27 Spain Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 28 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 29 Denmark Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 30 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 31 Sweden Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 32 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 33 Norway Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 34 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 37 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 38 China Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 39 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 41 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 42 India Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 45 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Country, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East & Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 62 Saudi Arabia Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 63 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 64 UAE Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Condition, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait Antibody Drug Conjugates (ADC) Contract Manufacturing Market, by Linker, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!